Respiratory Infections

New findings on an available 15-minute test show an approximate 81% sensitivity in detection of SARS-CoV-2.

New findings from the ASM 2021 World Microbe Forum suggest the emergency-authorized platform can capably detected the highly transmissible UK-borne variant.

Five people in 4 US states in the 20-21 influenza season contracted influenza A virus variants commonly spread among pigs, but without person-to-person spread.

Cartesian Therapeutics has created its therapy, Descartes-30, the first RNA cell therapy for acute respiratory distress syndrome (ARDS), and the company is now recruiting for a clinical trial.

Paratek’s omadacycline (Nuzyra) is granted approval for an oral-only dosing regimen in adults.

Rapid respiratory virus test results for children in an emergency department could be received too late to inform antibiotic prescribing.

The authorization change halves the required dose of the monoclonal antibody regimen, based on recent data.

A prospective study suggest co-infections and secondary infections are infrequent among COVID-19 patients, warranting the need for improved stewardship.

New research from Emory show a significant difference in institutional antibiotic prescribing after education on the value of PCT testing in infected patients last year.

The IL-6 targeting monoclonal antibody is linked to improved inflammatory and hemodynamic markers in hospitalized patients.

A concerted effort to increase flu vaccination during the COVID-19 pandemic resulted in more protection among a high-risk population, as well as educational opportunities for pharmacy students.

A new study in Canada suggests clinical practice guidelines should consider recommending days of amoxicillin for treatment of outpatient pediatric pneumonia in previously healthy children not requiring hospitalization.

The first US COVID-19 vaccine breaks ground again, as the first authorized for patients as young as 12 years old.

Rifapentine-moxifloxacin based anti-tuberculosis regimen shortened the conventional six-month course of treatment to four.

New real-world research suggest the vaccine may help provide control of the pandemic virus.

Our editor-in-chief writes on the role caregivers play in informing the public on the perks of a more vaccinated population.

New cohort analyses show the popular UK variant is linked to a higher viral load, though patients have not experienced worse likelihood of outcomes.

A new commentary from experts highlight the evolving understanding of antibody response in vaccinated transplant patients.

A month-long assessment in Wuhan sought the human origin of SARS-CoV-2. The investigators graded 4 possible scenarios.

Long-acting injectables for latent and active tuberculous (TB) might be a treatment option in the future and could open up the door to possibly bundling HIV and TB care together.

To mark World TB Day, a pair of experts break down the currently defined regimens for latent and active tuberculosis—and what may still come.

The small country's emphasis on accessible testing provided more up-to-date tracking, and opportunity for research into reinfection risk.

After a year of setbacks, AZD1222 has been associated with 100% prevention of severe COVID-19 in US trial participants. Could emergency authorization come soon?

An interview on perspectives learned from a nationwide PCR test database assessment.

Regardless of symptom status, the rate of participants positive for pan-immunoglobulins with neutralizing antibodies at baseline remained stable throughout 2020.

The new findings support increased protection from reinfection up to 6 months after first testing positive, though older patients are at greater risk of reinfection.

Researchers and clinicians continually failed to connect with the greater public on matters of the pandemic. What drove the divide between the already distanced groups?

A comparative study of same-day and seven-day TB test results show there is little difference in HIV treatment adherence or outcomes at 48 weeks.

The data additionally show a 94% prevention against asymptomatic SARS-CoV-2 infection, at a time when the country's dominant strain was the B.1.1.7 variant.

Though the product is authorized more than 70 countries, there is currently no reported US trial data, nor application for authorization to the FDA.